Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial

Kimberley M Heinhuis, Matteo Carlino, Markus Joerger, Massimo Di Nicola, Tarek Meniawy, Sylvie Rottey, Victor Moreno, Anas Gazzah, Jean-Pierre Delord, Luis Paz-Ares, Christian Britschgi, Russell J Schilder, Kenneth O'Byrne, Giuseppe Curigliano, Emanuela Romano, Poliana Patah, Rui Wang, Yali Liu, Gaurav Bajaj, Lillian L Siu

Research output: Contribution to journal › Article › peer-review

51 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor-Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors: A Phase 1/2a Dose-Escalation and Cohort-Expansion Clinical Trial'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science